MENTOR, Ohio – April 4, 2016 – STERIS Corporation and Controlled Contamination Services (CCS) recently collaborated to offer integrated services to their Life Sciences Customers. This relationship streamlines cleanroom sterilization and decontamination by incorporating STERIS’s patented VHP® Biodecontamination solutions with CCS’s comprehensive cleaning program.
“This unique venture allows us to offer unparalleled service to our Customers and to coordinate the project better than anyone else” said Larry Zanko, Manager, Global Biodecontamination Services for STERIS. “STERIS has the most highly regarded and respected products in the industry and CCS holds a rich history as experts with in-depth understanding of regulations and GMP requirements to meet the most stringent cleaning and decontamination needs.”
“Our Customers were already using both of our services, but generally making two phone calls to have a project handled,” said Chris Zines, CEO and co-founder of Controlled Contamination Services. “This venture unites two industry leaders in one call. Our sales teams are cross-trained to know exactly what product is required for each situation and exactly what protocol is necessary to maintain the highest standard in cleanrooms.”
Further, the collaboration between STERIS and CCS is unique in that it ensures that all steps in the cleaning and biodecontamination process are jointly handled to create one effective solution for your cleanroom.
Using a proprietary VHP process technology, STERIS Biodecontamination Services has handled complex projects such as Anthrax remediation and decontamination of large facilities. Most projects are completed in less than 24 hours. The low-temperature hydrogen peroxide dry vapor destroys a wide range of microorganisms including bacterial spores, viruses and fungi. The VHP does not condense on surfaces, making it a unique choice for sensitive materials including electronic equipment, HEPA filters and painted surfaces, and an environmentally friendly choice with residue-free byproducts.
CCS is an ISO 9001:2008 certified company with experience in GMP cleanroom cleaning, equipment assembly and cleaning, post construction cleaning and decontamination, hydrogen peroxide decontamination, emergency decontamination events and more.
Sales professionals from CCS and STERIS will jointly cover the United States to provide you with a comprehensive biodecontamination solution. In addition to teaming with CCS, STERIS recently acquired Micro-Clean, Southeastern Certification, and AGAPE Instruments Certification companies, expanding its capabilities and range of services.
STERIS's mission is to help our Customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit www.sterislifesciences.com.
About Controlled Contamination Services
Founded in 1993, CCS is the leading provider of Integrated Facility Services for the Life Sciences, High Tech, IT, and Aerospace and Defense industries. CCS provides its clients with comprehensive cleaning for GMP and non-GMP areas, hydrogen peroxide fogging, and technical service solutions that exceed the health, safety and environmental requirements for your business. CCS’s Data Center Division provided high quality cleaning and other services to large scale, raised floor data centers and computer rooms throughout the US. For more information, visit www.cleanroomcleaning.com.
This release and the conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date specified in this release and may be identified by the use of forward- looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "impact," "potential," "confidence," "improve," "optimistic," "deliver," "comfortable," "trend", and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described herein and in STERIS's, STERIS Corporation's and Synergy's other securities filings, including Item 1A of STERIS Corporation's Annual Report on Form 10-K for the year ended March 31, 2015 and in Synergy's annual report and accounts for the year ended 29 March 2015 (section headed "principal risks and uncertainties"). Many of these important factors are outside of STERIS's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in the press release or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results. References to products are summaries only and should not be considered the specific terms of the product clearance or literature. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) STERIS's ability to meet expectations regarding the accounting and tax treatments of the Combination, (b) the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in connection with the Combination within the expected time-frames or at all and to successfully integrate Synergy's operations with those of STERIS Corporation, (c) the integration of Synergy's operations with those of STERIS Corporation being more difficult, time-consuming or costly than expected, (d) operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected following the transaction, (e) the retention of certain key employees of Synergy being difficult, (f) changes in tax laws or interpretations that could increase our consolidated tax liabilities, including, changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, (g) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (h) the possibility that market demand will not develop for new technologies, products or applications or services, or business initiatives will take longer, cost more or produce lower benefits than anticipated, (i) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning notices or letters, government investigations, the outcome of any pending FDA requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect STERIS's performance, results, prospects or value, (j) the potential of international unrest, economic downturn or effects of currencies, tax assessments, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (k) the possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS's products and services, (l) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with STERIS's businesses, industry or initiatives including, without limitation, those matters described in STERIS Corporation's Form 10-K for the year ended March 31, 2015 and Synergy's annual report and accounts for the year ended 29 March 2015 and other securities filings, may adversely impact STERIS's performance, results, prospects or value, (m) the possibility that anticipated financial results or benefits of recent acquisitions, including the Combination, or of STERIS's restructuring efforts will not be realized or will be other than anticipated and (n) the effects of the contractions in credit availability, as well as the ability of STERIS's Customers and suppliers to adequately access the credit markets when needed.